Hypertriglyceridemia: rationale, design and implementation of the Australian Hypertriglyceridemia Registry

Jing Pang, Stephen C.h. Li, Dick C. Chan, David R. Sullivan, Ann-marie Woodward, Gerald F. Watts

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review
Hypertriglyceridemia (HTG) is a risk factor for atherosclerotic cardiovascular disease (ASCVD), aortic stenosis, hepatic steatosis and pancreatitis. We briefly review the aetiology and treatment of HTG and familial chylomicronemia syndrome (FCS), as well as the implementation of a clinical quality registry for improving care, the Australian Hypertriglyceridemia (AUSTRIG) Registry.
Recent findings
There is a need to improve the detection of individuals with severe HTG and FCS, who could benefit from more intense and novel treatments to prevent end-organ damage. Patient registries provide valuable data for advancing care of individuals with severe HTG at high risk of acute pancreatitis, steatohepatitis and ASCVD. However, there is a paucity of registries of such patients. We outline the design and implementation of the AUSTRIG Registry.
Summary
Clinical registries can be employed in many ways for improving outcomes for patients with HTG, through the collation and analysis of data for enabling health service planning, clinical trials and audits, and for better informing and empowering registrants.
Original languageEnglish
Pages (from-to)131-140
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume29
Issue number2
Early online date21 Jan 2022
DOIs
Publication statusPublished - Apr 2022

Fingerprint

Dive into the research topics of 'Hypertriglyceridemia: rationale, design and implementation of the Australian Hypertriglyceridemia Registry'. Together they form a unique fingerprint.

Cite this